PODD
Insulet Corporation
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- Strong revenue growth of +30.7% and a positive operating margin of 17.5% provided meaningful support to the growth and profitability factors, anchoring the composite score.
- The sharp decline in net income (-40.9%) and diluted EPS (-39.8%), combined with a 2026Q1 momentum pullback, prevented the score from reaching the higher range.
- Zero scores on both the dividend and macro theme factors weighed on the composite, contributing to the final total model score of 45.5/100.
Why Not Higher
- The dramatic contraction in net income and EPS in FY2025, despite robust revenue growth, signals a profitability quality issue that the model penalized significantly.
- The absence of a dividend and the failure of the Diabetes/GLP-1/Metabolic Health theme assignment to translate into a positive theme score both held the composite back.
Data Confidence
8 / 10
High — most data fields present
Why This Score
Grounded in figures from this company's SEC EDGAR filings — not a restatement of the score itself.
Revenue grew from FY2024's $2,071,600,000 to FY2025's $2,708,100,000, a gain of +30.7%, but net income fell -40.9% over the same period (FY2024: $418,300,000 to FY2025: $247,100,000), and diluted EPS declined -39.8% from FY2024's $5.78 to FY2025's $3.48.
The model rewarded the strong top-line expansion but penalized the sharp contraction in bottom-line profitability, producing a mid-range score that reflects the tension between accelerating revenue and deteriorating earnings.
In FY2025, Insulet posted an operating margin of 17.5%, a net margin of 9.1%, and a return on assets of 7.7%.
The model rewarded a healthy operating margin and positive returns across the board; the net margin, while positive, is meaningfully below the operating margin, suggesting below-the-line costs tempered an otherwise solid profitability profile.
In FY2025, Insulet carried a debt-to-equity ratio of 0.61 against total assets of $3,190,400,000.
A debt-to-equity ratio below 1.0 suggests a moderate leverage position, and the sizable asset base provides a degree of balance-sheet scale; however, the absence of additional liquidity or coverage metrics in the available filing data limits a fuller assessment, which is reflected in the mid-range score.
Quarterly revenue rose from $649,100,000 in 2025Q2 to a peak of $783,700,000 in 2025Q4 before pulling back to $761,700,000 in 2026Q1. Net income followed a similar arc, climbing from $22,500,000 in 2025Q2 to $101,600,000 in 2025Q4 and then easing to $91,100,000 in 2026Q1. Operating income showed a comparable pattern, peaking at $146,200,000 in 2025Q4 and retreating to $122,100,000 in 2026Q1.
The model captured a broadly improving trend through 2025Q4 across all three metrics, but the 2026Q1 pullback in revenue, net income, and operating income introduced deceleration that tempered the momentum score into the mid-range.
Insulet Corporation does not currently pay a dividend; this is a genuine characteristic of the company, not a data limitation.
The model assigns a score of zero for this factor when no dividend is paid, as income-oriented criteria cannot be satisfied without a distribution to shareholders.
Insulet is assigned to the macro themes of Diabetes, GLP-1, and Metabolic Health.
Although the company is mapped to actively tracked and high-profile macro themes, this assignment did not translate into a positive score under the model's current methodology for this factor.
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Insulet Corporation delivered strong top-line growth of +30.7% in FY2025, with revenue rising to $2,708,100,000, but this was offset by a sharp -40.9% decline in net income to $247,100,000 and a -39.8% drop in diluted EPS to $3.48, creating a meaningful tension between accelerating revenue and deteriorating earnings. Profitability metrics remain positive, with a 17.5% operating margin and 9.1% net margin in FY2025, though the gap between the two suggests notable below-the-line cost pressures. The balance sheet carries a moderate debt-to-equity ratio of 0.61 against total assets of $3,190,400,000, and quarterly momentum showed improvement through 2025Q4 before a modest pullback in 2026Q1. The absence of a dividend and a zero score on macro theme translation weighed on the composite, producing a total model score of 45.5/100 and a Medium risk rating with a Research Further label.
Plain English
Insulet is growing its sales fast, but its profits have dropped sharply at the same time, and it pays no dividend, so the overall score lands in the middle — good enough to look into further, but not a clear standout yet.
Bull Case vs. Bear Case
Bull Case
- Revenue expanded +30.7% year-over-year to $2,708,100,000 in FY2025, demonstrating strong top-line momentum in the diabetes and metabolic health space.
- Operating margin of 17.5% in FY2025 reflects a healthy core business, and quarterly net income climbed from $22,500,000 in 2025Q2 to $101,600,000 in 2025Q4, suggesting improving earnings power through the year.
- A debt-to-equity ratio of 0.61 and total assets of $3,190,400,000 indicate a moderately leveraged balance sheet with meaningful scale.
Bear Case
- Net income fell -40.9% from $418,300,000 in FY2024 to $247,100,000 in FY2025, and diluted EPS dropped -39.8% from $5.78 to $3.48, signaling significant bottom-line deterioration despite strong revenue growth.
- Revenue and operating income both pulled back in 2026Q1 — revenue fell to $761,700,000 from a peak of $783,700,000 in 2025Q4, and operating income declined to $122,100,000 from $146,200,000 — introducing deceleration concerns.
- Insulet pays no dividend, which eliminates any income return component and may limit appeal for a broad set of investors.
What Could Change the Picture
Bullish Triggers
- A sustained re-acceleration in quarterly revenue and net income beyond 2025Q4 peaks, combined with narrowing of the gap between operating and net margins, would suggest the below-the-line cost pressures are resolving.
- Consistent improvement in diluted EPS back toward FY2024 levels would indicate that the sharp earnings decline was transitory rather than structural.
Bearish Triggers
- If the 2026Q1 pullback in revenue and operating income deepens in subsequent quarters, it would confirm that the growth trajectory is decelerating more meaningfully than the current data suggests.
- A further widening of the gap between the 17.5% operating margin and the 9.1% net margin would indicate worsening below-the-line costs that could erode profitability further.
Risk Profile
Medium RiskInsulet carries a moderate leverage position with a debt-to-equity ratio of 0.61 and a sizable asset base of $3,190,400,000, but limited additional liquidity data constrains a fuller balance-sheet assessment. The 2026Q1 pullback in revenue, net income, and operating income after a strong 2025Q4 introduces near-term execution risk and warrants monitoring.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.